Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Nelipepimut-S Plus GM-CSF |
Synonyms | |
Therapy Description |
Nelipepimut-S Plus GM-CSF comprises a ERBB2 (HER2) targeted peptide vaccine (E75) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), which potentially results in increased immune response against ERBB2 (HER2) expressing tumor cells (PMID: 31036542). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Nelipepimut-S Plus GM-CSF | E75 Plus GM-CSF|nelipepimut-S plus sargramostim|NeuVax Plus GM-CSF | HER2 (ERBB2) Vaccine 14 | Nelipepimut-S Plus GM-CSF comprises a ERBB2 (HER2) targeted peptide vaccine (E75) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), which potentially results in increased immune response against ERBB2 (HER2) expressing tumor cells (PMID: 31036542). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02636582 | Phase II | Sargramostim Nelipepimut-S Plus GM-CSF | Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer | Completed | USA | 0 |